AA
TLSA icon

AlphaMark Advisors’s Tiziana Life Sciences TLSA Stock Holding History

AlphaMark Advisors’s Portfolio TLSA Stock Details TLSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,589
Closed -$309K – 812
2024
Q2 		$309K Buy
+4,589
New +$3.35K 0.11% 164

Other funds holding TLSA

SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ZF
Zhang Financial Portage, Michigan $3.42B AUM 23.04% 1-Year Est. Return
AFP
Ausdal Financial Partners Davenport, Iowa $2.25B AUM 20.11% 1-Year Est. Return
EL
EWA LLC Pittsbugh, Pennsylvania $548M AUM 35.14% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

AlphaMark Advisors's TLSA Position: Q3 2024 in Review

AlphaMark Advisors sold out of Tiziana Life Sciences (TLSA) in Q3 2024, closing a stake of 4,589 shares — an estimated $309K sold.

AlphaMark Advisors first reported a position in TLSA in Q2 2024 and held it in 1 quarter. The position peaked at $309K in Q2 2024. 30 funds tracked by Wall St. Rank hold TLSA as of Q3 2024.

  • AlphaMark Advisors reported no remaining Tiziana Life Sciences position as of Q3 2024 after selling out during the quarter.
  • AlphaMark Advisors sold 4,589 Tiziana Life Sciences shares in Q3 2024, an estimated $309K.
  • AlphaMark Advisors first reported a position in Tiziana Life Sciences in Q2 2024 and held it in 1 quarter.
  • AlphaMark Advisors's Tiziana Life Sciences position peaked at $309K in Q2 2024.
  • 30 funds tracked by Wall St. Rank held Tiziana Life Sciences as of Q3 2024.

Based on AlphaMark Advisors's 13F filing for Q3 2024, filed 16 Oct 2024.